ATG3 and precursor B-cell acute lymphoblastic leukemia: In addition, ROC curve analyzes revealed that ADAM17 and ATG3 showed high clinical performance (AUC = 0.989 and AUC = 0.956, respectively), reinforcing that EVs enriched by the proteins may represent valuable biomarkers in B-ALL (63).